Organovo is at the forefront of developing innovative 3D bioprinted human tissues aimed at enhancing drug discovery and safety testing. Their proprietary ExVive™ technology enables the creation of complex, functional human tissues, such as liver, kidney, and intestinal models, which closely mimic native organ physiology. This technology allows for advanced modeling of various diseases, including nonalcoholic fatty liver disease (NAFLD) and drug-induced liver injury, providing researchers with valuable insights into drug responses and toxicological effects. The use of 3D bioprinted tissues facilitates high-content screening and the evaluation of therapeutic interventions, significantly improving the drug development process.

In addition to their focus on drug discovery, Organovo's bioprinted tissues are also utilized for safety testing and disease modeling. Their research has demonstrated the ability to model tumor phenotypes and assess nephrotoxicity, among other applications. By leveraging their expertise in tissue engineering and bioprinting, Organovo aims to revolutionize the way diseases are studied and treatments are developed, ultimately leading to more effective therapies and improved patient outcomes. Their commitment to advancing the field of regenerative medicine is evident through their ongoing clinical studies and presentations at major scientific conferences.

United States

We are pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic key aspects of human biology and disease. We intend to fundamentally alter the drug discovery landscape by the development of novel therapies for disease which have a much higher chance of efficacy in the clinic focused on human primary cell 3D models of disease that more faithfully recapitulate disease processes.   Learn more at www.organovo.com.

Organovo

Company Details